Novartis Market Outlook Forecasts and Analysis to 2012

With headquarters in Basel, Switzerland, Novartis is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, high revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. In 2006 - ten years after its inception - Novartis generated total net sales of $37bn worldwide.

Novartis Market Outlook 2012 Report, examines the Novartis group independently and critically, through comprehensive research and analysis. Importantly, visiongain discusses Novartis in the context of the wider pharmaceutical industry and market. This market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, visiongain applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, Novartis 2007-2012 concentrates on the following essential aspects of the company:

Detailed analysis of Novartis divisions and its products, including Sandoz

Sales forecasts for key products by therapeutic area

Discussions of issues affecting the relevant market segments, including competitor analysis

Sales forecasts for all the Novartis divisions and the overall group

Drivers and opportunities for Novartis

Restraints and threats facing the company

Discussions of company strategy in the context of the market

Pipeline developments and their implications for the future

Strategic alliances and licensing

International operations

Novartis appears to have a golden touch that even other leading global pharmaceutical companies envy. In 2005, Novartis generated the fourth-highest sales in the global pharmaceutical industry, coming behind Pfizer, GSK and Sanofi-Aventis respectively. With its above-average growth, visiongain predicts that Novartis will rise even higher in the ranks of pharmaceutical giants within the foreseeable future. In particular, there will be significant developments in R&D and international operations.

Unique benefits to you when you order this report

- Full searchable report when you buy the company or corporate editions

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

This in-depth, business critical report is over 230+ pages of analysis, charts, forecasts and business breakdowns of how Novartis will develop over the next 5 years. An in-depth critique of their pipeline and their recent acquisitions and launches. With an analytical look at key products, their work in R&D, an assessment of their recent portfolio and pipeline throughout their therapeutic areas. Also includes additional information such as financials, agreements and corporate events. This is the one-stop business information stop for Novartis information.

Competitors, partners and companies seeking strategic alignments with a leading pharmaceutical company cannot afford to ignore developments in Novartis. And if you cannot afford to ignore Novartis, you cannot afford to ignore this report.

Publication Date: 27/02/07

Pages: 226

PDF Format
Table of Contents

Price
Single User Licence $3998.00
Department Licence 5 Users $7998.00
Company-wide Intranet Licence $11,998.00